Holen Sie sich die Stockscreener-App
3.50
2.51%
-0.09
Schlusskurs vom Vortag:
$3.59
Offen:
$3.58
24-Stunden-Volumen:
553.96K
Relative Volume:
0.75
Marktkapitalisierung:
$670.95M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-7.9545
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
+3.55%
1M Leistung:
+8.70%
6M Leistung:
+1.45%
1J Leistung:
-10.03%
1-Tages-Spanne:
$3.49
$3.605
1-Wochen-Bereich:
$3.35
$3.66
52-Wochen-Spanne:
$2.705
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Vergleichen Sie ABUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.50 | 647.94M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Will Arbutus Biopharma Corporation bounce back from current support2025 Major Catalysts & Growth Focused Entry Reports - Newser
Applying chart zones and confluence areas to Arbutus Biopharma CorporationCEO Change & Long-Term Capital Growth Strategies - Newser
Multi asset correlation models including Arbutus Biopharma Corporation2025 Risk Factors & AI Forecasted Entry and Exit Points - Newser
Published on: 2025-08-20 02:54:05 - Newser
Chart overlay techniques for tracking Arbutus Biopharma CorporationMarket Performance Report & Reliable Breakout Forecasts - Newser
Understanding Arbutus Biopharma Corporation’s price movementMarket Activity Summary & Low Risk High Win Rate Stock Picks - Newser
Sentiment analysis tools applied to Arbutus Biopharma CorporationMarket Trend Report & Stock Portfolio Risk Control - Newser
Technical analysis overview for Arbutus Biopharma Corporation stockWatch List & Stepwise Trade Signal Guides - Newser
Measuring Arbutus Biopharma Corporation’s beta against major indicesTrade Risk Report & Expert Approved Momentum Trade Ideas - Newser
Custom watchlist performance reports with Arbutus Biopharma CorporationPortfolio Value Summary & Low Drawdown Investment Ideas - Newser
Is Arbutus Biopharma Corporation stock entering bullish territoryJuly 2025 Update & High Accuracy Trade Alerts - Newser
Published on: 2025-08-19 03:41:21 - Newser
Published on: 2025-08-19 01:06:42 - Newser
Is Arbutus Biopharma Corporation stock reversal real or fakeQuarterly Performance Summary & Low Risk High Win Rate Picks - Newser
Real time scanner hits for Arbutus Biopharma Corporation explainedMarket Growth Report & Fast Momentum Stock Entry Tips - Newser
Volatility clustering patterns for Arbutus Biopharma CorporationJuly 2025 Intraday Action & Verified Swing Trading Watchlists - Newser
Can volume confirm reversal in Arbutus Biopharma CorporationMarket Performance Summary & Weekly Breakout Stock Alerts - Newser
Forecasting Arbutus Biopharma Corporation price range with options dataJuly 2025 Earnings & High Win Rate Trade Alerts - Newser
Real time social sentiment graph for Arbutus Biopharma CorporationQuarterly Portfolio Report & Daily Volume Surge Signals - Newser
Exit strategy if you’re trapped in Arbutus Biopharma CorporationPortfolio Update Report & Stepwise Trade Signal Guides - Newser
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Chardan Capital Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
XTX Topco Ltd Increases Position in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corporation stock outlook for YEARWeekly Growth Portfolio Performance Summary - Newser
Is Arbutus Biopharma Corporation stock ready for a breakoutStrategy Playbook for Risk Controlled Trades - Newser
News impact scoring models applied to Arbutus Biopharma CorporationMomentum-Based Prediction for Quick Returns - Newser
Arbutus Biopharma Corporation stock momentum explainedTrading Watchlist with Real Time Filters - Newser
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
How to integrate Arbutus Biopharma Corporation into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
What moving averages say about Arbutus Biopharma CorporationFree Smart Money Tracking Signal Generator - Newser
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Position Decreased by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Applying big data sentiment scoring on Arbutus Biopharma CorporationTechnical Safety Zone Pattern Recognition - Newser
Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Upgraded by Wall Street Zen - Defense World
Is now a turning point for Arbutus Biopharma CorporationFree Alpha Focused Technical Trade Signals - Newser
When is the best time to buy Arbutus Biopharma Corporation stockPortfolio Safety Metrics and Return Analysis - Newser
Arbutus Biopharma Returns to Profitability as It Regains Global Rights to Lead Hepatitis B Drug - MyChesCo
What risks could impact Arbutus Biopharma Corporation stock performanceLong Term Stock Growth Plan Suggestions - Newser
Arbutus: Q2 Earnings Snapshot - Connecticut Post
Arbutus Biopharma Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Arbutus Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
Arbutus Biopharma Reports Q2 Earnings of $2.523mln, Revenue of $10.739mln, EPS of $0.01 - AInvest
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 an - GuruFocus
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma Reports Q2 2025 Revenue of $10.7M and Appoints New Board Members - SSBCrack
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):